Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
Medtronic (NYSE: MDT) reported Q1 FY27 revenue of $9.8B, up 13.7% YoY, and raised FY27 guidance. Key growth areas include Cardiovascular (18.9%) and Neuroscience (9.3%). The company also announced strategic investments and partnerships. GAAP EPS was $1.14, non-GAAP EPS was $1.45.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift are likely to drive immediate buying pressure, while the expanded product portfolio may support longer‑term growth.
Market read
First‑report earnings with raised guidance for a large‑cap med‑tech firm; high trading relevance.
What to watch
Potential headwinds from foreign‑exchange volatility and integration risks of recent acquisitions.
Background
Medtronic's Q1 FY27 earnings release includes detailed segment performance, new product clearances, and strategic investments.
Ticker impact
Medtronic reported Q1 FY27 results with revenue up 13.7% and raised FY27 organic revenue growth guidance to 7.25‑7.75% and non‑GAAP EPS guidance to $5.94‑$6.00.
upside potential of 4‑6% over the next week as investors price in higher growth expectations.
The company delivered better‑than‑expected earnings and raised guidance, a material catalyst for a large‑cap medical‑technology stock.
Market effects
Positive momentum for the broader healthcare technology sector as Medtronic sets a higher growth benchmark.
U.S. and European med‑tech stocks may see modest gains on the back‑test of Medtronic's results.
Reinforces confidence in global demand for cardiovascular and surgical robotics solutions.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback on profit‑taking.
Key entities
- CompanyMedtronic plc
Global healthcare technology leader.
- ExecutiveGeoff Martha
Chairman and CEO of Medtronic.
- ExecutiveThierry Piéton
Chief Financial Officer of Medtronic.
